araag2/HINT huggingface dataset:
Clinical trial NCT00449865 (phase 3, status: terminated)
Conditions: parkinson's disease
ICD codes: G20
Drugs: creatine
SMILES: CN(CC(O)=O)C(N)=N
Reason stopped: 
    futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to give informed consent and willing to commit to long-term follow-up

          -  PD (asymmetric features including slowness (bradykinesia) plus resting tremor and/or
             rigidity) within 5 years of diagnosis

          -  Treated/responsive to dopaminergic therapy (dopamine agonists or levodopa) for at
             least 90 days, but not more than 2 years.

        Exclusion Criteria:

          -  Use of creatine 14 days prior to baseline or during the study

          -  History of known hypersensitivity or intolerability to creatine

          -  Any unstable or clinically significant condition that would impair the subject's
             ability to comply with long term study follow-up

          -  Other know or suspected causes of parkinsonism (e.g. metabolic, drug induced, etc.),
             or any significant features suggestive of a diagnosis of atypical parkinsonism.
Clinical trial NCT00683618 (phase 3, status: completed)
Conditions: hypercholesterolemia
ICD codes: E78.01, E78.00, Z83.42
Drugs: rosuvastatin, atorvastatin
SMILES: CC(C)C1=NC(=NC(C2=CC=C(F)C=C2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(=O)O)N(C)S(C)(=O)=O, CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Treated for or diagnosed hypercholesterolemia or have had a high risk with
             hypercholesterolemia

          -  LDL-C between 3.36mmol/L and 6.5 mmol/L if not treated with statin or between
             2.6mmol/L and 4.14 mmol/L

          -  Fasting triglyceride less than 4.52mmol/L

        Exclusion Criteria:

          -  History of statin induced myopathy

          -  Unstable or uncontrolled cardiovascular diseases

          -  Familial dysbetalipoproteinemia
Clinical trial NCT00604383 (phase 3, status: completed)
Conditions: diabetic retinopathy
ICD codes: H35.23, H35.20, H35.21, H35.22, E10.3553, E11.3553, E13.3553
Drugs: ruboxistaurin, placebo
SMILES: [H][C@@]1(CN(C)C)CCN2C=C(C3=CC=CC=C23)C2=C(C(=O)N=C2O)C2=CN(CCO1)C1=CC=CC=C21, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 1 or Type 2 diabetes mellitus

          -  18 years or older

          -  Meet specific requirements for diabetic retinopathy

          -  Free of severe or chronically disabling conditions, except diabetes, diabetic
             retinopathy and diabetic macular edema

          -  Hemoglobin A1c (HbA1C) ≤13.0%

        Exclusion Criteria:

          -  History of panretinal photocoagulation for diabetic retinopathy, conditions that might
             affect the progression of diabetic retinopathy, or unstable angina

          -  Investigators, site personnel directly affiliated with the study and their families

          -  Presence of eye disorders that may affect the progression of diabetic retinopathy or
             cause vision loss

          -  Presence of medical disorder, cancer, or elevated laboratory measurements that could
             represent a safety risk during the study

          -  Women who are pregnant, breastfeeding, intend to become pregnant, or who are sexually
             active without using an acceptable method of birth control
Clinical trial NCT01425203 (phase 3, status: completed)
Conditions: chronic hepatitis c genotype 1
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: boceprevir, placebo, ribavirin
SMILES: NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion criteria:

          -  body weight ≥40 kg and ≤125 kg

          -  previously documented CHC genotype 1 infection;

          -  must have a liver biopsy with histology consistent with CHC and no other etiology

          -  if cirrhosis present, must have an ultrasound within 6 months of the screening visit
             (or between screening and Day 1) with no findings suspicious for hepatocellular
             carcinoma (HCC)

          -  agree to use acceptable methods of contraception with partner

          -  previously untreated with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV or
             failing prior treatment with pegylated-interferon (either alfa-2a or alfa-2b) plus RBV

        Exclusion criteria:

          -  co-infected with the human immunodeficiency virus (HIV) or hepatitis B virus
             (Hepatitis B surface antigen [HBsAg] positive).

          -  required discontinuation of previous interferon or ribavirin regimen for an adverse
             event (possibly or probably related)

          -  treatment with ribavirin within 90 days and any interferon-alpha, based on the
             amendment, should be within 1 month prior to screening

          -  treatment with any investigational drug within 30 days of the screening visit in this
             trial

          -  evidence of decompensated liver disease including, but not limited to, a history or
             presence of clinical ascites, bleeding varices, or hepatic encephalopathy

          -  diabetic and/or hypertensive with clinically significant ocular examination findings

          -  clinical diagnosis of substance abuse of specified drugs within specified timeframes

          -  any known pre-existing medical condition that could interfere with the participant's
             participation in and completion of the trial
Clinical trial NCT00364013 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: panitumumab, folfox regimen
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Man or woman at least 18 years old

          -  Diagnosis of metastatic colorectal cancer

          -  At least 1 uni-dimensionally measurable lesion of at least 20 mm per modified RECIST

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Paraffin-embedded tumor tissue from the primary tumor or metastasis available for
             central analyse Exclusion Criteria:

          -  History or known presence of central nervous system (CNS) metastases

          -  History of another primary cancer, except: Curatively treated in situ cervical cancer,
             or Curatively resected non-melanoma skin cancer, or Other primary solid tumor
             curatively treated with no known active disease present and no treatment administered
             for ≥ 5 years before randomization

          -  Prior chemotherapy or systemic therapy for the treatment of metastatic colorectal
             carcinoma except: adjuvant fluoropyrimidine-based chemotherapy or prior
             fluoropyrimidine therapy administered solely for the purpose of radiosensitization

          -  Prior oxaliplatin therapy

          -  Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, cetuximab) or
             treatment with small molecule EGFr inhibitors (eg, erlotinib)

          -  Clinically significant cardiovascular disease (including myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) 1 year prior to randomization History of interstitial lung disease (eg,
             pneumonitis or pulmonary fibrosis) or evidence of interstitial lung disease on
             baseline chest computed tomography (CT) scan

          -  Active inflammatory bowel disease or other bowel disease causing chronic diarrhea
             (defined as > Common terminology criteria (CTC) grade 2 [CTCAE version 3.0])

          -  Peripheral sensory neuropathy with functional impairment
Clinical trial NCT00529373 (phase 3, status: terminated)
Conditions: postmenopausal osteoporosis
ICD codes: N95.0, N95.2
Drugs: odanacatib, placebo for odanacatib
SMILES: CC(C)(F)C[C@H](N[C@@H](C1=CC=C(C=C1)C1=CC=C(C=C1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Postmenopausal women (for at least 5 years) who are ≥65 years of age and have low bone
             mineral density

          -  Ambulatory (able to walk)

        Exclusion Criteria:

          -  Must not be taking osteoporosis therapy or have a metabolic bone disorder other than
             osteoporosis

          -  Has or has had a hip fracture

          -  Currently participating in another drug study
Clinical trial NCT00397553 (phase 3, status: completed)
Conditions: diabetes mellitus, type 1
ICD codes: E10.65, E10.9, E10.21, E10.36, E10.41, E10.42, E10.44
Drugs: insulin glulisine
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diabetes mellitus, Type 1

          -  HbA1c 6.5-11.0%

          -  BMI <35 kg/m²

        Exclusion Criteria:

          -  Diabetes mellitus, Type 2

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT00335153 (phase 3, status: completed)
Conditions: advanced parkinson's disease
ICD codes: G20
Drugs: levodopa-carbidopa intestinal gel
SMILES: C[C@@](CC1=CC(O)=C(O)C=C1)(NN)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Idiopathic Parkinson's disease (PD) according to United Kingdom Parkinson's Disease
             Society (UKPDS) Brain Bank Criteria

          -  Levodopa-responsive with severe motor fluctuations

          -  Recognizable off and on state (motor fluctuations) confirmed by diary

        Exclusion Criteria:

          -  Diagnosis is unclear or a suspicion of other parkinsonian syndromes exists such as
             secondary parkinsonism

          -  Undergone surgery for the treatment of PD

          -  Contraindications to levodopa (such as narrow angle glaucoma)
Clinical trial NCT00051272 (phase 3, status: completed)
Conditions: major depressive disorder (mdd)
ICD codes: F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: extended-release bupropion hydrochloride
SMILES: CC(NC(C)(C)C)C(=O)C1=CC(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of Major Depressive Disorder (MDD) with current duration lasting 12
             weeks but no greater than 2 years.

          -  Subjects must engage in sexual activity that leads to orgasm at least once every two
             weeks.

          -  Subject must have normal orgasmic function and be willing to discuss with
             investigator.

        Exclusion Criteria:

          -  Subjects that have arousal or orgasm dysfunction.

          -  Has previously failed to respond to two adequate trials of antidepressants in past 2
             years.

          -  Subject has other unstable medical disorders.

          -  Subject has a positive urine test for illicit drug use at screening.
Clinical trial NCT00067444 (phase 3, status: completed)
Conditions: depressive disorder, major, major depressive disorder (mdd)
ICD codes: F33.0, F33.1, F33.9, F32.0, F32.1, F32.9, F33.40, F25.1, F32.89, F33.8, F33.0, F33.1, F33.9, F32.0
Drugs: paroxetine cr
SMILES: FC1=CC=C(C=C1)[C@@H]1CCNC[C@H]1COC1=CC2=C(OCO2)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of Major Depressive Disorder (MDD).

          -  Current major depressive episode at screen at least 2 months duration.

          -  Must be at least 60 years of age.

        Exclusion Criteria:

          -  Patients with a primary diagnosis other than MDD.

          -  Patients with a history of schizophrenia, schizoaffective disorder, bipolar disorder
             or dementia.

          -  Patients with a history of brief depressive episodes lasting less than 8 weeks.

          -  Patients receiving formal psychotherapy within 12 weeks of study.

          -  Patients who are suicidal.

          -  Patients who have received electroconvulsive therapy or transcranial magnetic
             stimulation within 6 months prior to screening.

          -  Patients with a history or seizure disorders.
Clinical trial NCT00220961 (phase 3, status: completed)
Conditions: impaired glucose tolerance, type 2 diabetes
ICD codes: R73.02, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: pioglitazone, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women

          -  All ethnic groups

          -  18 years of age and older

          -  Impaired glucose tolerance by glucose tolerance test (fasting glucose 95-125 mg/dl and
             2 hr glucose of 140-199 mg/dl)

          -  At least one of the following:

               -  One or more components of the insulin resistance syndrome (HDL < 40 mg/dl in
                  females and <35 mg/dl in males, fasting triglycerides > 150 mg/dl, blood pressure
                  > 135/85 mmHg, BMI > 24 kg/m2, waist circumference > 102 cm in men and > 88 cm in
                  women)

               -  One or more first degree relatives with type 2 diabetes

               -  History of gestational diabetes

               -  Polycystic ovarian disease

               -  Minority ethnic background (Mexican American, African American, Asian and Pacific
                  Islanders, Native American)

        Exclusion Criteria:

          -  Type 2 diabetes

          -  Previously treated with thiazolidinediones (ever) or metformin (within one year)

          -  Previously treated with a sulfonylurea, a meglitinide, an alpha glucosidase inhibitor
             for more than a week within last year or within the 3 months prior to randomization

          -  Previously treated with insulin (other than during pregnancy) for more than one week
             within the last year or within the 3 months prior to randomization

          -  Cardiovascular disease

          -  Hospitalization for treatment of heart disease or stroke in past 6 months

          -  New York Heart Association Functional Class > 2

          -  Left bundle branch block or third degree AV block

          -  Aortic stenosis

          -  SBP > 180 mmHg or DBP > 105 mmHg

          -  Renal disease

          -  Anemia

          -  Hepatitis

          -  GI diseases (pancreatitis, inflammatory bowel disease)

          -  Recent or significant abdominal surgery

          -  Advanced pulmonary disease

          -  Chronic infections

          -  Weight loss > 10% in past 6 months

          -  Pregnancy and childbearing

          -  Major psychiatric disorders

          -  Excessive alcohol intake

          -  Thiazide use > 25 mg per day

          -  Non-selective beta blockers

          -  Niacin

          -  Systemic glucocorticoids

          -  Weight loss or weight gain medication

          -  Thyroid disease-suboptimally treated

          -  Active endocrine diseases (Cushing's, acromegaly)

          -  Plasma triglycerides over 400 mg/dl (despite treatment)

          -  History bladder cancer

          -  Hematuria
Clinical trial NCT00179621 (phase 3, status: completed)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: lenalidomide 5 mg, lenalidomide 10 mg, placebo
SMILES: NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Must understand and voluntarily sign an informed consent form

          -  Age 18 years at the time of signing the informed consent form

          -  Documented diagnosis of myelodysplastic syndromes (MDS) that meets International
             Prognostic Scoring System (IPSS) criteria for low to intermediate-1-risk disease and
             has an associated del 5q(31) cytogenetic abnormality

          -  Red blood cell (RBC) transfusion dependent anaemia defined as not having any 56 days
             without a RBC transfusion within at least the immediate 112 days

          -  Must be able to adhere to the study visit schedule and other protocol requirements

          -  Women of childbearing potential must have a negative pregnancy test prior to inclusion

        Exclusion Criteria:

          -  Pregnant or lactating females

          -  Prior therapy with lenalidomide

          -  Proliferative (white blood cell (WBC)= 12,000/mL) chronic myelomonocytic leukemia
             (CMML)

          -  Prior >= grade-2 (using the National Cancer Institute (NCI)'s Common Terminology
             Criteria for AEs (CTCAE) (v 3.0)) allergic reaction to thalidomide

          -  Prior desquamating (blistering) rash while taking thalidomide

          -  Prior history of malignancy other than MDS (except basal cell or squamous cell
             carcinoma or carcinoma in situ of the cervix or breast) unless the subject has been
             free of disease for >3 years

          -  Use of cytotoxic chemotherapeutic agents or experimental agents (agents that are not
             commercially available) for the treatment of MDS within 28 days

          -  Less than 6 months since prior allogeneic bone marrow transplantation

          -  Less than 3 months since prior autologous bone marrow or stem cell transplantation

          -  Less than 28 days since prior myelosuppressive anticancer biologic therapy

          -  Recombinant human erythropoietin (rHuEPO) therapy received within 28 days

          -  Known human immunodeficiency virus (HIV-1) positivity

          -  Any serious medical condition or psychiatric illness that will prevent the subject
             from signing the informed consent form or will place the subject at unacceptable risk
             if he or she participates in the study
Clinical trial NCT01044030 (phase 3, status: completed)
Conditions: acute otitis media
ICD codes: H65.03, H65.00, H65.01, H65.02, H65.06, H65.193, H65.04
Drugs: xylitol syrup, placebo
SMILES: OC[C@H](O)[C@@H](O)[C@H](O)CO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Six months to five years of age

          -  General good health

          -  History of at least three episodes of AOM in previous 12 months, at least one of which
             occurred within the previous six months

          -  English or Spanish speaking

        Exclusion Criteria:

          -  History of tympanostomy tubes

          -  Intestinal malabsorption or chronic diarrhea

          -  Diabetes mellitus

          -  Any inborn error of metabolism

          -  Parent/guardian unreachable by telephone

          -  Known allergy to any of the study solution components (xylitol, sorbitol, sodium
             carboxymethylcellulose, potato starch, glycerin, potassium sorbate, natural berry
             flavoring).
Clinical trial NCT00449878 (phase 3, status: completed)
Conditions: cystic fibrosis, exocrine pancreatic insufficiency
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4, K86.81
Drugs: liprotamase, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Females of childbearing potential must be willing to use birth control

          -  Diagnosis of CF based upon the following criteria:

               -  two clinical features consistent with CF; and

                    -  either genotype with two identifiable mutations consistent with CF, OR

                    -  sweat chloride >60 mEq/L by quantitative pilocarpine iontophoresis

          -  Clinically stable with no evidence of acute upper or lower respiratory tract infection

          -  PI determined by fecal elastase <100 µg/g stool measured at screening

          -  Able to take pancreatic enzyme supplementation in the form of capsules

          -  Able to perform the testing (e.g., stool collections) and inpatient stays required for
             this study, as judged by the Investigator

          -  Baseline coefficient of fat absorption (CFA) less than or equal to 80%

        Exclusion Criteria:

          -  CFA >80% at Baseline

          -  Pregnancy, breastfeeding or of childbearing potential and not willing to use birth
             control during the study

          -  History of fibrosing colonopathy

          -  History of liver transplant, lung transplant or significant surgical resection of the
             bowel

          -  Any acute or chronic diarrheal illness unrelated to PI

          -  Unable to discontinue enteral tube feedings during the study

          -  Known hypersensitivity to food additives

          -  Inability to consume the diet required by the study, in the judgment of the
             Investigator

          -  Participation in an investigational study of a drug, biologic, or device not currently
             approved for marketing within 30 days prior to screening

          -  Abnormal liver function (except for patients with Gilbert Syndrome)

          -  Signs and/or symptoms of liver cirrhosis, portal hypertension or documented liver
             disease unrelated to CF

          -  Distal intestinal obstruction syndrome (DIOS) in the last six months prior to
             screening

          -  Unable to discontinue the use of pancreatic enzymes

          -  Any condition that the Investigator believes would interfere with the intent of this
             study or would make participation not in the best interest of the patient

          -  Patient is unlikely to complete the study, as determined by the Investigator
Clinical trial NCT00171067 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: valsartan, lisinopril
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O, CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with mild to moderate hypertension with a mean sitting diastolic blood
             pressure (MSDBP) > 85 and < 110 mmHg for non-treated patients. Previously treated
             patients with MSDBP < 110 mmHg. Treated is defined as having taken medication until <
             2 days prior to Visit 1

          -  Positive urine spot test with Micral dipstick (detection of urinary albumin
             concentration of at least 50 mg/l) at Visit 1 (day -21).

          -  Confirmation of MAU of at least 2 out of 3 measurements determined in the first
             morning urine samples performed at Visit 1 day-21), Visit 2 (day -14) or Visit 3 (day
             -7). MAU is defined for male patients as urinary albumin creatinine ratio (UACR) > 2.5
             mg/mmol and < 25.0 mg/mmol and for female patients as UACR > 3.5 mg/mmol and < 35.0
             mg/mmol at both visits.

        Exclusion Criteria:

          -  Evidence of renal impairment as determined by any one of the following:

               -  serum creatinine clearance < 30 ml/min as determined by Cockroft and Gault
                  formula [Cockroft and Gault, 1976] and/or

               -  serum creatinine > 1.25 x ULN at Visit 1,

               -  a history of dialysis, or

               -  a history of nephrotic syndrome.

          -  Serum potassium values <3.5 mmol/l or >5.5 mmol/l at Visit 1

          -  Any medical condition which might significantly alter the urinary excretion of albumin

        Other protocol-defined exclusion criteria may apply.